Log In
BCIQ
Print this Print this
 

Myalept, metreleptin (Myalepta)

  Manage Alerts
Collapse Summary General Information
Company Novelion Therapeutics Inc.
DescriptionRecombinant form of human leptin
Molecular Target
Mechanism of Action 
Therapeutic ModalityBiologic: Protein
Latest Stage of DevelopmentMarketed
Standard IndicationLipodystrophy
Indication DetailsTreat complications of leptin deficiency in patients with congenital or acquired generalized lipodystrophy; Treat complications of leptin deficiency in patients with partial lipodystrophy; Treat lipodystrophy
Regulatory Designation U.S. - Expanded Access (Treat lipodystrophy);
U.S. - Fast Track (Treat lipodystrophy)
PartnerAmgen Inc.;
Shionogi & Co. Ltd.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

4

$11,468.3M

$8,325.0M

$1,400.0M


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone
Get a free BioCentury trial today